Morning, Marco. Another thin journal week — NEJM's September 3 issue and Annals' September 1 issue carry nothing that changes an overnight admission, and SHM, ACP, AAFP and USPSTF were all quiet. So the top of the report is news you'd want anyway: Washington put new sanctions on the company that keeps Cuba's grid running, the Gulf fight went into a fourth day with no talks, and FDA approved the first cancer drug whose trigger is a blood test rather than a scan. The debate is Florida's own — Amendment 3 — because both sides finally put named leaders in front of microphones this week. Mets hit five homers last night. Read, then sleep.
A · Top Stories
Cuba
US sanctions Cuba's grid-parts importer and a Castro grandson
On Thursday the State Department and Treasury added Fidel Ernesto Castro (grandson of Raúl) and Abapet, the state company that imports the special equipment and spare parts for Cuba's power plants, to the sanctions list. The AP quotes sanctions analyst Brett Erickson that the intent is to push "critical machinery offline" and that Havana will procure parts through costlier back channels, feeding inflation. Daily outages already exceed 24 hours in parts of the island; one Havana grandmother told the AP she'd had no power since Sunday. Foreign Minister Bruno Rodríguez called it "collective punishment"; Rubio said the targets are "part of the corrupt Castro financial and intelligence network." The announcement landed hours after Cuban officials briefed the press on the economic reforms approved in June. AP via Local 10
Why it matters: This is the first sanction aimed squarely at grid maintenance rather than fuel. If Abapet can't source parts, the six-collapse year gets worse, and the downstream effect you see in Cape Coral is arrivals with months of untreated hypertension, diabetes and dialysis gaps.
Talking point: Ask case management whether the hospital has a current workflow for newly arrived Cuban patients without records or insurance — the number is likely to rise this fall.
World · Update
Update: Gulf fighting into day four; no talks, oil ~$91–96, Hormuz transits in single digits
Since Wednesday's edition: Iran fired missiles and drones at Ahmad al-Jaber Air Base in Kuwait and at targets in the UAE on Wednesday; CENTCOM posted video Thursday of strikes on Iranian targets including two ships along the strait. Vice President Vance said Thursday there will be no talks "until Iran stops attacking commercial shipping," disputed the Kuhestak wedding-strike account, and claimed Iran's control of Hormuz is "effectively gone." The data say otherwise: the Joint Maritime Information Center reports independent tracking shows single-digit daily transits in each direction against a pre-war average of 138, and Iran hit at least 13 commercial vessels in August, the last of which (tanker Sidr, Monday) killed two seafarers. Brent spiked past $96 after the Kuwait strike and traded near $91 Friday, on track for a ~9% weekly gain. USNI News · CBS · CNBC · Al Jazeera
Why it matters: The administration's transit numbers (30–40/day) and the maritime industry's (under 10) can't both be true. USNI's sourcing says stockpiles are drawn down enough that one hurricane or one more refinery hit moves supply from "low but sustainable" to critical — that is the input to your hospital's fuel, plastics and pharmaceutical-freight contracts on a 6–12 month lag.
Watch: Whether the US-facilitated convoy count (44 on Sept 1–2) recovers or falls after this week's exchange; that number, not the oil price, is the leading indicator.
Oncology · FDA
FDA approves camizestrant — first cancer drug triggered by a blood test, not a scan
Accelerated approval Friday for AstraZeneca's oral SERD camizestrant, with a CDK4/6 inhibitor, in ER+/HER2– advanced breast cancer that has acquired an ESR1 mutation on first-line therapy. In the pivotal trial patients were switched when circulating tumor DNA showed the mutation, before radiographic progression; median progression-free survival was 16.0 months versus 9.2 months for continuing the aromatase inhibitor. FDA describes it as the first oncology approval based on a ctDNA-detected resistance mutation. FDA press release
Why it matters: Two practical things. Oral endocrine therapy will now change mid-course on a lab result the patient may not fully understand, so "what are you taking for the breast cancer?" gets less reliable on med rec. And the ctDNA-switch model is the template every other tumor group will copy — expect "molecular progression" to appear in oncology notes as a reason for a regimen change with no imaging attached.
Small move: Add "any recent change to your cancer pills?" to the admission script for women on endocrine therapy; a switch within the last 4–6 weeks is worth flagging to the day team.